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Epoxyeicosatrienoic acids (EpETrEs), produced from arachidonic acid via cytochrome P450 (CYP) epoxygenases, regulate
inflammation, angiogenesis, cellular proliferation, ion transport and steroidogenesis. EpETrE actions are regulated through
their metabolism to diols (dihydroxyeicosatrienoic acids; DiHETrE) via the enzyme soluble epoxide hydrolase (EPHX2). We
set out to determine, therefore, whether EpETrE generating (epoxygenases CYP2C8, 2C9, 2C19, 2J2, 1A2 and 3A4) and metaboliz-
ing (EPHX2) enzymes are expressed in the primate corpus luteum (CL). CL were isolated from rhesus macaques during the early
(day 3–5 post-LH surge), mid (day 6–8), mid-late (day 10–12), late (day 14–16) and very-late (day 17–19: menses) luteal phase of
natural menstrual cycles. EPHX2 mRNA levels peaked in mid-late CL (5-fold when compared with early CL, P < 0.05) and
remained elevated in the late CL. Ablation of pituitary LH secretion and luteal steroid synthesis significantly reduced (P <
0.05) EPHX2 mRNA levels in the mid-late CL, with progestin replacement being insufficient to restore its level of expression
to control values. EPHX2 protein was localized to large and small luteal cells, as well as vascular endothelial cells. The
EpETrE-generating CYP epoxygenase 2J2, 2C9 and 3A4 genes were also expressed in the macaque CL. While CYP2J2 mRNA
levels did not significantly change through the luteal phase, CYP2C9 and CYP3A4 levels were significantly (P < 0.05) higher in
the mid-late phase when compared with the early phase. CYP2C9, 2J2 and 3A4 proteins were each localized to the large luteal
cells, with 2C9 and 2J2 also being present in the small luteal, stromal and endothelial cells. These studies demonstrate for the
first time that an EpETrE generating and metabolizing system exists in the primate CL, with the latter being regulated by LH
and steroid hormone(s).
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Introduction
It is well known that arachidonic acid can be converted to prostaglan-
dins (PG) and leukotrienes via PG endoperoxide synthases (PGHS)
and lipoxygenases, respectively. Additionally, certain cytochrome
P450 (CYP) family members, collectively termed epoxygenases,
convert arachidonic acid to four different regioisomers of epoxyeico-
satrienoic acid (5,6-EpETrE; 8,9-EpETrE; 11,12-EpETrE and
14,15-EpETrE). The individual CYP epoxygenases, primarily belong-
ing to the 2C and 2J family, preferentially form different EpETrE
regio- and stereoisomers. EpETrEs, in turn, can be further metabolized
to their corresponding vicinal diol (dihydroxyeicosatrienoic acids or
DiHETrEs) via the enzyme soluble epoxide hydrolase (EPHX2).
EpETrEs affect numerous biological processes in a variety of differ-
ent organ systems (Newman et al., 2005; Spector and Norris, 2006).
For example, EpETrEs were reported to induce vasodilation and regu-
late vascular tone by activating large conductance Kþ channels
(Hecker et al., 1994; Larsen et al., 2006). EpETrEs also limit endo-
thelial inflammatory responses by inhibiting NF-kB activation,
enhance fibrinolysis by increasing tissue plasminogen activator
expression and regulate renal ion transport by controlling Naþ/Kþ
transporter activity (Node et al., 1999,2001; Zhao and Imig, 2003).
At the molecular and cellular level, EpETrEs were demonstrated to
serve as critical intermediates in epidermal growth factor signaling,
inhibitors of apoptosis and pro-mitogenic factors (Kroetz and
Zeldin, 2002; Spector and Norris, 2006). In addition, depending on
the cell type analysed, EpETrEs either elevated or inhibited PGHS-2
activity or expression (Peri et al., 1997,1998; Fang et al., 1998).
The ability of the EpETrEs to affect the above-described processes
is also dependent upon the level of EPHX2 activity as their conversion
to DiHETrEs results in decreased biological potency (Fang et al.,
1998; Spector and Norris, 2006).
Despite the wealth of information regarding EpETrE synthesis,
metabolism and action in various tissues, little information exists regard-
ing these activities in the ovary. Human granulosa cells obtained from
IVF procedures were reported to produce and metabolize EpETrEs in
vitro (Zosmer et al., 1990; Van Voorhis et al., 1993; Zosmer et al.,
2002). Additionally, CYP epoxygenase expression, EpETrE production
and EPHX2 expression were demonstrated in the porcine ovulatory fol-
licle, where it was noted that the level of EpETrEs and their metabolites,
particularly 11,12- and 14,15- isomers, corresponds with the level of
follicular fluid estradiol (E2) (Newman et al., 2004). Moreover, Van
Voorhis and co-workers (1993) demonstrated that low doses (5–
10 nM) of 14,15-EpETrE enhance E2 levels, whereas higher doses
(1–50 mM) reduce E2 concentrations in human granulosa cell cultures.
# The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For
Permissions, please email: journals.permissions@oxfordjournals.org Page 1 of 8
Molecular Human Reproduction pp. 1–8, 2007
doi:10.1093/molehr/gam044 Mol. Hum. Reprod. Advance Access published June 12, 2007
We recently demonstrated that soluble EPHX2 mRNA is expressed
at high levels in the mouse preovulatory follicle and developing
corpus luteum (CL) (Hennebold et al., 2005). A parallel increase in
EPHX2 enzyme activity was noted throughout a stimulated estrous
cycle with the highest levels of activity being observed in the post-
ovulatory interval. We set out, therefore, to determine whether a
similar EpETrE metabolizing system exists in CL obtained from
rhesus monkeys, a species that possesses a long, well-defined luteal
phase (Stouffer, 2004). Studies were also conducted to characterize
the presence and regulation of the genes encoding EpETrE synthesiz-




The general care and housing of rhesus monkeys (Macaca mulatta) at the Oregon
National Primate Research Center (ONPRC) was described previously (Wolf
et al., 1990). All protocols were approved by the ONPRC Animal Care and
Use Committee, and conducted in accordance with NIH Guidelines for the
Care and Use of Laboratory Animals. Menstrual cycles of adult female rhesus
monkeys were monitored daily. Six days after menses, daily blood samples
were collected by saphenous venipuncture. Serum was collected, and stored at
2208C, until assayed for E2 and progesterone levels by specific electrochemilu-
minescent assays (Roche Elecsys 2010) through the Endocrine Services Labora-
tory, ONPRC (Young et al., 2002). The first day of low serum E2 following the
mid-cycle peak has been demonstrated to correspond with the day after the LH
surge, and was therefore termed Day 1 of the luteal phase (Duffy et al., 1999).
Tissues
CL (n ¼ 3–4 stage) were isolated from anesthetized monkeys during an aseptic
ventral midline laparotomy as previously described (Duffy et al., 2000). CL
were collected during the early (days 3–5 post-LH surge), mid (days 6–8),
mid-late (days 10–12), late (days 14–16) and very-late (days 17–19; mense)
luteal phase. Each CL was divided into thirds, with 2 out of the 3 portions
being frozen in liquid N2. The frozen samples were then stored at 2808C
until they were used for RNA and protein isolation. The remaining portion
of each CL was fixed in 10% neutral buffered formalin for 5–7 days
(Richard-Allen Scientific, Kalamazoo, MI), dehydrated in a series of ethanol
solutions (50, 70 and 100%) and stored after being embedded in paraffin.
Hormone ablation and replacement protocol
Hormone ablation and replacement was performed in adult rhesus monkeys
beginning on day 9 of the luteal phase (mid-late) as previously reported
(Young et al., 2004). In this treatment protocol, females were randomly
assigned to one of five groups (n ¼ 4–5/group): control (no treatment);
antide (ANT) (GnRH antagonist, 3 mg/kg body weight, Ares Serono; LH abla-
tion); ANT þ recombinant human (rh)LH (40 IU tid; Ares Serono; LH replace-
ment); ANT þ rhLH þ Trilostane (TRL; 600 mg, a 3b-hydroxysteroid
dehydrogenase, or 3b-HSD, inhibitor from Sanofi Research; steroid ablation);
ANT þ rhLH þ TRL þ R5020 (2.5 mg, a nonmetabolizable progestin; Prome-
gestone; DuPont/NEN; progesterone replacement). Serum E2 and progesterone
levels were analysed daily (Young and Stouffer, 2004). On day 12, CL were
removed via laparotomy and flash frozen in liquid N2. RNA was isolated
using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s direc-
tions. RNA integrity was confirmed for each sample using an Agilent Technol-
ogies 2100 Bioanalyzer.
RT–PCR
Total RNA was isolated using TRIzol (Invitrogen) according to the manufac-
turer’s directions. After RNA isolation, reverse transcription (RT) was per-
formed on 1 mg DNase-treated RNA using Moloney murine leukemia virus
reverse transcriptase (Invitrogen) for 1 h at 378C. PCR was performed in a
25 ml volume using Clontech reagents and the following cycling parameters
(MJ Research, Watertown, MA): initial denaturation, 948C for 1 min; denatura-
tion, 948C for 30 s; annealing (see Table 1 for primer sequences and optimal
annealing temperatures) for 45 s and primer extension at 728C for 1 min. The
number of cycles necessary to ensure a linear phase of amplification was deter-
mined empirically. PCR products (5 ml) were electrophoresed through a 1.7%
agarose gel stained with 0.1 mg/ml ethidium bromide. Gels were visualized
using a gel documentation system (Gel Doc 2000, BioRad, Hercules, CA)
and subsequently analysed densitometrically with Quantity One software
(BioRad). All values were normalized to the internal standard peptidylprolyl
isomerase A (PPIA; also known as cyclophilin A).
Real-time PCR
PCR was performed using pooled luteal cDNA and primers designed against
the human EPHX2 gene (Table 1). The resulting rhesus macaque EPHX2
PCR product was sequenced and used to design rhesus monkey-specific
primers (Invitrogen) and a TaqMan# probe (Primer Express Software,
Applied Biosystems, Foster City, CA) for the real-time PCR assay (for
primer sequences see Table 1). The rhesus monkey EPHX2 TaqMan# probe
sequence was 50-6FAM-ACTGGCCACCGCCCTCACTCTCT-TAMRA-30. A
matrix of varying primer concentrations was employed to determine optimal
primer concentrations.
Real-time PCR was performed using the TaqMan# PCR Core Reagent Kit
with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems)
as previously described (Young et al., 2002). 18S rRNA levels were monitored
simultaneously in each sample to normalize the target signal. Amplifications
were conducted in a 10 ml final volume containing 250 nmol/l TaqMan#
EPHX2 probe (labeled with the reporter dye FAM), 300 nmol/l EPHX2
forward and reverse primers, 250 nmol/l TaqMan# 18S probe (labeled with
the 50 reporter dye VIC) and 50 nmol/l forward and reverse 18S primers. The
PCR reactions were conducted in sealed 96-well optical plates with thermal
cycler conditions of: 2 min at 508C, 10 min at 958C and 40 cycles of 15 s at
958C (denaturation) and 1 min at 608C (primer annealing/extension). An
internal standard curve, generated from five 10-fold dilutions of cDNA
pooled from all CL samples, was used for relative mRNA quantification. The
RNA equivalent values were divided by complimentary 18S RNA equivalent
values derived from the same internal standard curve.
Table 1: Oligonucleotide sequence and optimal annealing temperatures of PCR primers
Gene Forward primer Reverse primer Annealing
temperature (8C)
CYP3A4 50 TGATGGCTCTAACAATGAC 30 50 TTCTAAACAATGGGCAAAG 30 52
CYP1A2 50 TCAAGCACAGCAAGAAGG 30 50 GGTTTACGAAGACACAGCA 30 50
CYP2C19 50 CTTGTGGAGGAGTTGAGA 30 50 CGAGGGTTGTTGATGTC 30 50
CYP2C9 50 CTTTATTGATTGCTTCCTGATG 30 50 GTAGCACAGAAGTCAGGGAAA 30 60
CYP2C8 50 GCAGGATAGGAGCCAC 30 50 TGTAGCACGGAAGTCAG 30 51
CYP2J2 50 TTTCTGCTCGCTGCTGACTTT 30 50 AACCTTCTTTGCTCCTTCCA 30 60
EPHX2 50 GAGTTGGTATTCTTGGAGG 30 50 TGTTGGGATTTGCTGG 30 56
PPIA 50 CCAGGGTTTATGTGTCAGGG 30 50 TGCCTTCTTTCACTTTGCCA 30 56
EPHX2 real-time PCR 50GGAGGTGTGCTGGTGTGGTA30 50 GGATTGCTGGTATGAAGGGAGTA 30 60
Irusta et al.
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Western blot
Proteins were extracted from individual CL samples by homogenization in lysis
buffer (50 mM Tris–HCl, 150 mM NaCl, 10% glycerin and 1% Triton X-100)
containing a protease inhibitor cocktail (Sigma, St. Louis, MO). Samples were
centrifuged at 10 000g for 10 min at 48C. The supernatant was collected and
protein concentration was determined by Lowry assay (BioRad). Proteins
(40 mg) were separated using 4–15% Tris–HCl sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred onto nitrocellulose mem-
branes. Rabbit polyclonal anti-human EPHX2 (kindly provided by Dr. Bruce
Hammock, University of California, Davis, CA) and anti-human b-Actin
(ACTB; Abcam, Cambridge, MA) were used at a 1:1000 dilution. ACTB anti-
body (1:5000 dilution) was used to verify equivalent protein loading. The blots
were incubated for 1 h with peroxidase-conjugated anti-rabbit IgG antibody
(1:4000; Santa Cruz Biologicals, Santa Cruz, CA) and the bands visualized
using a chemiluminescent detection system (Santa Cruz Biologicals).
Immunohistochemistry
CL sections (6 mm) were deparaffinized with xylene and hydrated through a
graded series of ethanol. Sections were incubated in phosphate-buffered
saline (PBS) prior to pressure cooker antigen retrieval in citrate buffer (Citra;
BioGenex Laboratories, Inc., San Ramon, CA). Endogenous peroxidase
activity was then quenched with a 10 min incubation in 3% H2O2. Sections
were placed in a blocking buffer (1.5% normal goat serum, NGS, in PBS)
for 1 h at room temperature. Antibodies that recognize human CYP2C9
(Abcam, Cambridge, MA), CYP2J2 (kindly provided by Dr Zeldin DC,
NIEHS), CYP3A4 (Abcam, Cambridge, MA) and EPXH2 were diluted to
1:100 in NGS/PBS and incubated with tissue sections at room temperature
for 1 h or at 48C overnight. Primary antibodies were detected using a biotiny-
lated anti-rabbit IgG secondary antibody (7.5 mg/ml; Vector Laboratories) and
a peroxidase substrate kit (ABC Elite Kit, Vector Laboratories). A non-specific,
species and isotype-matched antibody was used as a negative control at the
same concentration as the test antibody. The images were captured using an
Olympus BX40 microscope equipped with a digital Olympus DP12 camera
(40 and 100 magnification).
Statistical analysis
Statistical evaluation of mean differences among experimental groups was per-
formed by ANOVA using the Sigma Stat software package (SPSS Inc.,
Chicago, IL). To isolate significant differences (P , 0.05) between groups,
the Student–Newman–Keuls method was used for the pair-wise multiple
comparisons.
Results
EPHX2 mRNA expression and protein
immunolocalization in the rhesus macaque CL
We set out to determine whether EPHX2 is highly expressed in the
rhesus macaque CL as was observed in the developing mouse CL
(Hennebold et al., 2005). Using primers generated from the human
EPHX2 gene sequence; EPHX2 mRNA was also detected in the
primate CL (data not shown). Moreover, real-time PCR analysis
of EPHX2 gene expression in the rhesus macaque CL revealed a sig-
nificant increase in mRNA levels after the early luteal phase, with
peak levels being observed in CL isolated from the mid-late luteal
phase (5-fold relative to early CL, P , 0.05; Fig. 1A).
To determine whether there was a corresponding change in EPHX2
protein levels, western blot analysis was performed. In parallel with
EPHX2 gene expression, EPHX2 protein expression was minimal in
homogenates isolated from early CL (Fig. 1B), but then increased to
peak levels in mid-late and late CL.
The cellular distribution of EPHX2 was subsequently examined in
the rhesus macaque CL by immunohistochemistry (IHC). Immunor-
eactivity was widely observed in the cells that comprise the CL,
including the large luteal cells, and small luteal cells (Fig. 1C). Fur-
thermore, EPHX2 expression was prominent in the endothelial cells
lining individual blood vessels. The negative control (non-immune
IgG) antibody exhibited no immunoreactivity (Fig. 1C, inset).
Regulation of EPHX2 gene expression in the
rhesus macaque CL
Using a gonadotropin and steroid hormone ablation protocol, the regu-
lation of EPHX2 gene expression in the macaque CL at the mid-late
stage (days 9–12 post-LH surge) of the luteal phase was investigated.
CL isolated from LH depleted animals (e.g. ANT-treated), showed a
significant reduction (2.9-fold, P , 0.05) in EPHX2 gene expression
when compared with untreated controls (Fig. 2). These levels were
restored to control values after LH replacement, demonstrating a posi-
tive regulation of luteal EPHX2 gene expression by LH. The adminis-
tration of Trilostane (steroid depletion, a 3b-HSD inhibitor) to
LH-replete animals (ANT þ LH), however, inhibited EPHX2
mRNA expression to levels observed in the ANT-only treatment
group (Fig. 2). Reduced EPHX2 gene expression in this group was
not fully restored to control or ANT þ LH levels following adminis-
tration of a nonmetabolizable progestin (R5020). The analysis of cir-
culating progesterone levels in the animals from which the individual
CL were taken verified that the gonadotropin and steroid ablation and
replacement treatments were effective for each group (data not shown,
previously reported in Young and Stouffer, 2004).
Epoxygenase gene expression and protein localization
in the rhesus macaque CL through the luteal phase
As the CYP epoxygenases are responsible for converting arachidonate
to EpETrEs, an endogenous substrate for EPHX2, studies were con-
ducted to determine if the epoxygenase genes are also expressed in
the primate CL. PCR primers were generated that correspond to
known primate epoxygenase genes (CYP1A2, CYP3A4, CYP2C8,
CYP2C9, CYP2C19 and CYP2J2) based on the available human
sequences. Of these, one CYP2J (CYP2J2) and one CYP2C
(CYP2C9) subfamily member was expressed in the primate CL
(Table 2). A member of the CYP3A subfamily (CYP3A4) was also
expressed in the rhesus macaque CL. Rhesus macaque liver was
used as a positive control (Ikeya et al., 1989; Wrighton et al., 1993;
Schuetz et al., 1994; Enayetallah et al., 2004), with all of the primer
sets for each epoxygenase gene amplifying a product of the appropri-
ate size. To ensure that each primer set successfully amplified the
correct cDNA, each PCR product was sequenced and compared
with the corresponding human epoxygenase gene. All rhesus
macaque CYP epoxygenase gene products were 96–99% homologous
to the corresponding human sequence (data not shown).
To determine if the CYP2J2, 2C9 and 3A4 epoxygenase genes are
differentially expressed in the rhesus macaque CL through the luteal
phase, semi-quantitative RT–PCR was performed. Semi-quantitative
RT–PCR was utilized in place of real-time PCR due to the fact that
the high degree of homology shared between the CYP epoxygenase
genes (95–99%) is problematic for designing specific real-time
Taqman# probes and primers. Also, through the use of this method-
ology, amplification of the correct product was established by ampli-
con size as well as the subsequent sequencing of the PCR product. As
such, CYP2C9 expression was significantly higher (P , 0.05) during
the mid-late luteal phase, when compared with the other stages of
the luteal phase (Fig. 3). CYP2J2 mRNA levels, however, did not
differ between CL obtained from any of the different luteal stages ana-
lysed (Fig. 3). Epoxygenase CYP3A4 expression in the rhesus monkey
CL was significantly (P , 0.05) elevated in mid-luteal phase and
remained high during mid-late and late stages when compared with
early and very-late luteal phases (Fig. 3).
EpETrE synthesis and metabolism in the rhesus macaque CL
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To determine the potential cellular site of EpETrE synthesis within
the primate CL, IHC was performed using antibodies that recognize
human 2J2, 2C9 and 3A4 epoxygenases. IHC was performed using
sections obtained from CL at the mid-late luteal phase, the stage at
which a high level of expression for each epoxygenase gene was
noted. Mid-late stage CL displayed positive CYP2C9 and 2J2 immu-
noreactivity within large luteal cells, small luteal and stromal cells, as
well as endothelial cells lining blood vessels (Fig. 4A, B). CYP2C9
and 2J2 staining, while apparent in small luteal and stromal cells,
was more intense in large luteal cells. CYP3A4 protein also localized
predominantly in the large luteal cells, with limited expression present
in the small luteal, stromal and endothelial cell populations (Fig. 4C).
Discussion
The EPXH2 gene encodes soluble EPHX2, an enzyme, i.e. highly con-
served between organisms (Newman et al., 2005) and is involved in
the conversion of lipid epoxides (e.g. EpETrEs) to their corresponding
Figure 1: EPHX2 expression and immunolocalization in the rhesus macaque CL. (A) Quantitative real-time PCR analysis of EPXH2 gene expression throughout the
monkey luteal phase. As described in Materials and Methods, CL were collected during the early (days 3–5 post-LH surge), mid (days 6–8), mid-late (days 10–12),
late (days 14–16) and very-late (days 17–19; menses) luteal phase. Data represent mean+SEM and significant differences (P , 0.05) between the luteal phases are
indicated by different letters. Values were standardized to internal 18S rRNA levels. (B) Western blot analysis of EPHX2 protein expression in homogenates gen-
erated from CL isolated at the different stages of the luteal phase. Liver was used as a positive control. (C) Immunolocalization of EPHX2 in rhesus macaque CL that
were surgically removed during the mid-late luteal phase. L, large luteal cells; S, small luteal and stromal cells; arrowheads, endothelial cells lining blood vessels.
Left panel: 40 magnification image. Right panel: 100 magnification of the boxed area indicated in the lower magnification (40) image. A species and isotype-
matched, non-immune antibody was used as a negative control at the same dilution as the test antibody (inset, mid-late CL).
Irusta et al.
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vicinal diols (e.g. DiHETrEs) (Chacos et al., 1983; Beetham et al.,
1995; Borhan et al., 1995; Yu et al., 2000). The EPHX2 enzyme
serves to alter the EpETrE/DiHETrE ratio and, thus, the potential of
these lipid epoxides to modulate various biological processes. In
this regard, Fang et al. (1998) demonstrated that 14,15-EpETrE
reduced PGE2 formation in smooth muscle cells, whereas
14,15-DiHETrE was incapable of eliciting this effect. EpETrEs also
serve as regulators of vascular tone through their capacity to hyperpol-
arize the underlying smooth muscle cells by activating large conduc-
tance Kþ channels (Hecker et al., 1994; Larsen et al., 2006). This
vasodilatory effect has also been shown to be dependent on the
level of endothelial cell EPHX2 activity and EpETrE metabolism
(Imig et al., 2005).
Despite the increasing lines of evidence regarding the role of
EpETrE formation and degradation in other tissues, little is known
about the existence of an EpETrE synthesizing and metabolizing
system in the ovary. Recently, we reported that the expression of
the mouse Ephx2 gene increased significantly just prior to and after
ovulation in animals undergoing a stimulated estrous cycle (Henne-
bold et al., 2005). Studies were conducted, therefore, to extend
these findings to primate CL isolated throughout the luteal lifespan
Figure 3: CYP epoxygenase mRNA expression in the rhesus macaque CL
through the luteal phase. (A) A representative RT–PCR gel illustrating
CYP2C9 (401 bp), CYP2J2 (338 bp) and CYP3A4 (267 bp) gene expression in
the rhesus macaque CL through the course of a natural luteal phase. PPIA
(235 bp) amplification served as an internal control. (B) Densitometric values
normalized to PPIA. Data are presented as the mean+SEM (n ¼ 4–5/stage).
Different letters indicate significant differences (P , 0.05) between groups.
Figure 2: Regulation of EPHX2 gene expression in the rhesus macaque CL
Relative expression of the EPHX2 gene was analysed by quantitative real-time
PCR (mean+SEM) throughout the luteal phase. CL were obtained from
untreated (control) animals; or those undergoing gonadotropin and steroid abla-
tion (ANT), gonadotropin replacement (ANT þ LH), gonadotropin replace-
ment with steroid ablation (ANT þ LH þ Trilostane or TRL) and
gonadotropin plus progestin replacement (ANT þ LH þ TRL þ R5020) proto-
cols. Treatments were initiated during the mid-late luteal phase (day 9), with
CL being isolated 3 days later (day 12). Values were standardized to the
internal control 18S rRNA. Data represent mean+SEM and significant differ-
ences (P , 0.05) between treatments and the untreated (control) animals are
indicated by different letters.
Table 2: Epoxygenase gene expression in rhesus macaque CL







aliver mRNA served as a positive control for epoxygenase gene expression,
with the resultant PCR products being sequenced to verify their identity.
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in the menstrual cycle. The expression of both EPHX2 mRNA and
protein peaked in the rhesus macaque CL during the mid-late and
late luteal stages of the macaque menstrual cycle. The mid-late
luteal phase is a point of transition between when the CL is at peak
function (i.e. maximal progesterone synthesis) to the onset of its phys-
iological regression (i.e. during the late luteal phase). Therefore, the
induction of EPHX2 expression during the mid-late and late luteal
phases suggests that this enzyme plays a role as an initiator and/or
effector of luteal regression. In the mouse ovary, increased Ephx2
gene expression after ovulation was observed primarily in luteinizing
granulosa cells of the developing CL as determined by in situ hybrid-
ization (Hennebold et al., 2005). By immunohistochemical analysis,
EPHX2 was localized to all cell types (e.g. large luteal, small luteal,
stromal and endothelial cells) within the rhesus macaque CL.
Vertebrate EPHX2 is an inducible gene product and a number of
studies have demonstrated hormonal regulation (Denlinger and
Vesell, 1989; Inoue et al., 1993; Inoue et al., 1995; Pinot et al.,
1995). For example, hepatic EPHX2 enzyme activity in mice is
under the control of the hypothalamic-pituitary-gonadal axis (Inoue
et al., 1995). In the present study, we demonstrate for the first time
that rhesus macaque EPHX2 gene expression is regulated by the luteo-
tropic hormone LH. Following the administration of the GnRH antag-
onist antide (ANT) to rhesus macaques for 3 days beginning on day 9
of the luteal phase, EPHX2 mRNA expression was significantly inhib-
ited. With the replacement of LH in ANT-treated animals, however,
EPHX2 mRNA levels were similar to those within CL taken from
control animals. Moreover, ablation of steroid hormone synthesis
through the administration of a 3b-HSD inhibitor (Trilostane) signifi-
cantly reduced EPHX2 gene expression to levels observed in CL
obtained from gonadotropin-depleted (i.e. ANT-treated) rhesus
monkeys. Supplemental progestin (R5020) only partially, but not sig-
nificantly, restored EPHX2 mRNA levels to control values. EPHX2
gene expression, therefore, is likely indirectly regulated through
steroid hormones other than progesterone, possibly including estro-
gens and androgens. A similar steroid dependent, but progesterone
independent, regulation of gene expression in the rhesus monkey CL
was reported for the metalloproteinase ADAMTS1 (a disintegrin
and metalloproteinase with thrombospondin repeats-1; Young and
Stouffer, 2004). Additional in vivo steroid ablation and replacement
studies, along with in vitro luteal cell experiments, will be required
to define which steroids are primarily involved in regulating luteal
EPHX2 gene expression. Furthermore, the partial restoration and
variability of EPHX2 gene expression taken from animals receiving
R5020 may be due to the limited number of CL available for analysis
(n ¼ 4) and, as such, may require additional samples from animals
undergoing steroid ablation and replacement protocols to resolve
this issue.
Since the EpETrEs are the primary endogenous substrates for
EPHX2, we subsequently determined whether the EpETrE generating
enzymes are also expressed in the rhesus macaque CL. Primate epox-
ygenase encoding genes include CYP2C8, 2C9, 2C19, 2J2, 1A2 and
3A4 (Rifkind et al., 1995; Wu et al., 1996; Zeldin et al., 1996;
Bylund et al., 1998; Ayajiki et al., 2003). Previous studies demon-
strated that ovarian samples taken from women of undetermined age
and menstrual cycle stage express epoxygenase genes belonging to
the CYP2C family (Klose et al., 1999). Additionally, cultured human
granulosa cells possess an epoxygenase activity, that is up-regulated
by LH (Zosmer et al., 1990). In the present study, the expression of
the CYP2J2, 2C9 and 3A4 genes were detected in the rhesus macaque
CL using a semi-quantitative RT–PCR approach. It was noted that
CYP2C9 and 3A4 mRNA expression increases in the mid-late and
mid-luteal phase, respectively, relative to CL isolated from the early
luteal phase. In contrast to CYP3A4 gene expression, CYP2C9 drops
at the late luteal phase. The CYP2J2 gene is constitutively expressed
throughout the luteal phase. Moreover, there was no significant
change in epoxygenase gene expression in CL isolated from animals
undergoing the gonadotropin and steroid hormone ablation and repla-
cement protocol (data not shown). When the cellular localization of
the CYP2J2, 2C9 and 3A4 proteins was determined by IHC at the
mid-late stage of the rhesus macaque luteal phase (i.e. at a point of
high levels of gene expression), it was noted that these three epoxy-
genases are mainly expressed in large luteal cells, with variable stain-
ing in small luteal cells and endothelial cells. More importantly,
however, these results demonstrate an overlap in CYP2C9, 2J2 and
3A4 expression with EPHX2 expression in the large luteal cells of
the rhesus macaque CL. Additionally, co-localization of EPHX2
Figure 4: Immunolocalization of CYP epoxygenase proteins in the rhesus macaque CL. IHC for (A) CYP2C9, (B) CYP2J2 and (C) CYP3A4 was performed using
sections obtained from rhesus macaque CL at the mid-late (days 10–12) stage of the luteal phase, a period of high gene expression for all three epoxygenases. L,
large luteal cells; S, small luteal and stromal cells; arrowheads, endothelial cells lining blood vessels. Top panels: low power magnification (40) images; Bottom
panels: 100 magnification corresponding to the boxed area indicated in the top (low magnification) panels. Negative controls (insets) included using a species and
isotype matched non-immune antibody in place of the specific anti-CYP antibody.
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with CYP2C9 and 2J2 in the endothelial cells of blood vessels indi-
cates that EpETrE actions may play a role in luteal vascular function,
with any activity being regulated by their metabolism to DiHETrEs.
Overlapping cellular expression between EPHX2 and CYP2C9 was
reported in a number of human tissues, including the uterus (Enayetal-
lah et al., 2004), thereby providing a system by which the synthesis,
metabolism and consequently EpETrE-dependent activities are
tightly controlled at a cellular level.
To our knowledge, this is the first time that the enzymes responsible
for EpETrE synthesis and metabolism have been characterized in the
primate CL. As such, these studies suggest a role for EpETrE synthesis
and metabolism in primate luteal physiology. The epoxygenase genes
CYP2C9 and 3A4 exhibit variable patterns of expression in the rhesus
macaque CL, with CYP2J2 being constitutively expressed throughout
the luteal phase of natural menstrual cycles. EPHX2 expression, on the
other hand, begins to increase in the mid-late luteal phase and plateaus
when luteal regression starts to take place (i.e. late luteal phase). The
changes in EpETrE synthesizing and metabolizing enzyme expression
during the CL lifespan likely alter the EpETrE/DiHETrE balance and,
thus, the degree to which luteal cell processes are regulated by the
arachidonate-derived epoxides.
Processes regulated by EpETrEs in other tissues that may be critical
for various aspects of luteal development, function and/or regression
include angiogenesis, inflammation, endothelial cell function and
apoptosis. Specifically, inhibition of apoptosis by EpETrEs occurs
through the activation of the phosphatidylinositol 3-kinase Akt signal-
ing pathway (Chen et al., 1999). The angiogenic effects of the EpETrEs
were also shown to utilize this pathway (Pozzi et al., 2005; Wang et al.,
2005; Zhang et al., 2006). EpETrEs serve as endothelium-derived
hyperpolarizing factors that cause relaxation of the underlying
smooth muscle cells of the vessels thereby increasing blood flow
(Fisslthaler et al., 1999; Fisslthaler et al., 2000; Campbell et al.,
2001; Pratt et al., 2001). Furthermore, in non-ovarian cells, EpETrEs
regulate production of PG through the regulation of PGHS-2 expression
or activity (Peri et al., 1997; Fang et al., 1998; Peri et al., 1998). Lastly,
EpETrEs produced in the rhesus macaque CL may regulate steroido-
genesis as each of the EpETrE isomers (5,6-, 8,9-, 11,12- and
14,15-EpETrE) have been shown to induce steroid synthesis in
human granulosa cells and mouse Leydig MA-10 cells (Van Voorhis
et al., 1993; Zosmer et al., 2002; Wang et al., 2006). The latter was
attributed to an EpETrE-dependent induction of steroidogenic acute
regulatory protein expression (Wang et al., 2006). The above-described
EpETrE activities taken together with the data presented herein
supports a role for these arachidonate-derived compounds in luteal
physiology. As such, future studies are warranted to further define
the processes that are affected by EpETrEs in primate luteal cells.
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